CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TAF8 (ImmuneEditome ID:129685)

1. Gene summary of enriched editing regions for TAF8

check button Gene summary
Gene informationGene symbol

TAF8

Gene ID

129685

GeneSynonymsII|NEDMLHB|TAF|TAF(II)43|TAFII-43|TAFII43|TBN
GeneCytomap

6p21.1

GeneTypeprotein-coding
GeneDescriptiontranscription initiation factor TFIID subunit 8|TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 43kDa|TATA box binding protein (TBP)-associated factor, RNA polymerase II, A, 45/50kDa|TBP-associated factor 43 kDa|TBP-associated factor 8|TBP-associated factor TAFII43|TBP-associated factor, RNA polymerase II, 43 kD|hTAFII43|protein taube nuss|taube nuss homolog|transcription initiation factor TFIID 43 kDa subunit
GeneModificationdate20230517
UniprotIDB4DZU5;Q7Z7C8;A0A8I5QJI2;A0A8I5QL44;A0A8I5KVM3;A0A0A0MRR3;A0A8I5KXI2;A0A8I5KTT0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr6:42051862-42053539:+ENST00000482926.1ENSG00000137413.14TAF8ncRNA_intronicAluSx,FLAM_A,AluSq2,LTR16A,Charlie1a,AluSx1,MIRbchr6:42051862-42053539:+.alignment
chr6:42077758-42082418:+ENST00000372977.6ENSG00000137413.14TAF8UTR3AluSq2,AluSz,L1MC5a,L1MD2,AluYb9,AluSz6,(GT)n,(GGTGG)nchr6:42077758-42082418:+.alignment
chr6:42077758-42082418:+ENST00000494547.4ENSG00000137413.14TAF8UTR3AluSq2,AluSz,L1MC5a,L1MD2,AluYb9,AluSz6,(GT)n,(GGTGG)nchr6:42077758-42082418:+.alignment
chr6:42084688-42085983:+ENST00000372982.7ENSG00000137413.14TAF8intronicAluSx1,MIRc,MLT1A0,L1ME4b,AluSx,AluJochr6:42084688-42085983:+.alignment
chr6:42084688-42085983:+ENST00000456846.5ENSG00000137413.14TAF8intronicAluSx1,MIRc,MLT1A0,L1ME4b,AluSx,AluJochr6:42084688-42085983:+.alignment


Top

2. Tumor-specific enriched editing regions for TAF8


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr6:42077758-42082418:+BRCAEER4.2687e-07image
ENSG00000137413.14,TAF8BRCAEAG8.9039e-07image
chr6:42077758-42082418:+LIHCEER1.8159e-02image
ENSG00000137413.14,TAF8LIHCEAG1.3094e-02image
chr6:42077758-42082418:+LUSCEER5.3155e-05image
ENSG00000137413.14,TAF8LUSCEAG7.3668e-05image
chr6:42077758-42082418:+PRADEER1.9407e-02image
ENSG00000137413.14,TAF8PRADEAG2.7565e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000137413.14,TAF8BLCAPathEAG2.0710e-023.4744e-020.1056image
chr6:42077758-42082418:+BLCAPathEER2.6970e-024.7988e-020.0991image
chr6:42077758-42082418:+HNSCPathEER1.1382e-022.7471e-03-0.1439image
ENSG00000137413.14,TAF8HNSCPathEAG1.1352e-022.7034e-03-0.1442image
ENSG00000137413.14,TAF8KIRPPathEAG1.6046e-021.3250e-030.2032image
chr6:42077758-42082418:+KIRPPathEER2.0758e-021.7849e-030.1978image
ENSG00000137413.14,TAF8READPathEAG4.0540e-024.8947e-02-0.1882image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for TAF8


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr6:42077758-42082418:+PCPGEERENSG00000176476,CCDC101-0.46854.7411e-071.4792e-08-0.4198imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr6:42077758-42082418:+PCPGEERENSG00000158615,PPP1R15B0.45491.5955e-066.0881e-080.4030imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAMast_cells_activatedGSVA_HALLMARK_TGF_BETA_SIGNALING
chr6:42077758-42082418:+PCPGEERENSG00000168096,ANKS3-0.45271.6257e-061.5617e-08-0.4191imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAGSVA_HALLMARK_ANDROGEN_RESPONSE
chr6:42077758-42082418:+PCPGEERENSG00000103245,NARFL-0.43793.9944e-067.3605e-08-0.4007imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAMast_cells_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr6:42077758-42082418:+UVMEERENSG00000167528,ZNF641-0.54771.2580e-031.6802e-05-0.5099imageNDGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_DN
chr6:42077758-42082418:+UVMEERENSG00000269888,RP11-3P17.50.53961.3574e-033.5584e-040.4327imageNTAF15NAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr6:42077758-42082418:+UVMEERENSG00000265806,MIR4292-0.52661.8892e-034.2721e-04-0.4274imageNNNAT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr6:42077758-42082418:+UVMEERENSG00000184402,SS18L1-0.51722.4801e-036.0381e-04-0.4172imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAMacrophages_M1GSVA_HALLMARK_KRAS_SIGNALING_DN
chr6:42077758-42082418:+UVMEERENSG00000272888,LINC01578-0.51692.5943e-032.0253e-05-0.5057imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr6:42077758-42082418:+UVMEERENSG00000139620,KANSL2-0.50623.0460e-032.9534e-05-0.4970imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr6:42077758-42082418:+PCPGEERENSG00000176476,CCDC101-0.46854.7411e-071.4792e-08-0.4198imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr6:42077758-42082418:+PCPGEERENSG00000158615,PPP1R15B0.45491.5955e-066.0881e-080.4030imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAMast_cells_activatedGSVA_HALLMARK_TGF_BETA_SIGNALING
chr6:42077758-42082418:+PCPGEERENSG00000168096,ANKS3-0.45271.6257e-061.5617e-08-0.4191imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAGSVA_HALLMARK_ANDROGEN_RESPONSE
chr6:42077758-42082418:+PCPGEERENSG00000103245,NARFL-0.43793.9944e-067.3605e-08-0.4007imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAMast_cells_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr6:42077758-42082418:+UVMEERENSG00000167528,ZNF641-0.54771.2580e-031.6802e-05-0.5099imageNDGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_DN
chr6:42077758-42082418:+UVMEERENSG00000269888,RP11-3P17.50.53961.3574e-033.5584e-040.4327imageNTAF15NAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr6:42077758-42082418:+UVMEERENSG00000265806,MIR4292-0.52661.8892e-034.2721e-04-0.4274imageNNNAT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr6:42077758-42082418:+UVMEERENSG00000184402,SS18L1-0.51722.4801e-036.0381e-04-0.4172imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAMacrophages_M1GSVA_HALLMARK_KRAS_SIGNALING_DN
chr6:42077758-42082418:+UVMEERENSG00000272888,LINC01578-0.51692.5943e-032.0253e-05-0.5057imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr6:42077758-42082418:+UVMEERENSG00000139620,KANSL2-0.50623.0460e-032.9534e-05-0.4970imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

4. Enriched editing regions and immune related splicing for TAF8


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr6:42077758-42082418:+
TGCTEERESENSG00000170004.12chr177907352:7907488:7907600:7907702:7907893:7908019-0.35154.2304e-031.7214e-07-0.4151imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAB_cells_naiveGSVA_HALLMARK_ADIPOGENESIS
ENSG00000137413.14,TAF8
TGCTEAGA3ENSG00000169925.12chr9134036031:134036320:134034700:134034826:134034700:1340348290.27014.6783e-024.2618e-070.4092imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZFP36;ZNF184NAT_cells_follicular_helper
chr6:42077758-42082418:+
TGCTEERIRENSG00000256453.1chr5140670793:140671750:140672444:140672906-0.32681.0137e-021.6535e-07-0.4092imageNHNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000137413.14,TAF8
TGCTEAGA5ENSG00000170222.11chr1710706437:10706550:10704909:10705527:10704909:107056150.26364.8155e-022.8754e-070.4107imageNADAR;BUD13;CELF2;DDX3X;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LARP4B;LIN28B;MOV10;MSI1;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1NAB_cells_naiveGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000137413.14,TAF8
TGCTEAGESENSG00000170004.12chr177907352:7907488:7907600:7907702:7907893:7908019-0.34834.2390e-031.2993e-07-0.4188imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_ADIPOGENESIS
chr6:42077758-42082418:+
TGCTEERIRENSG00000146830.9chr7100679506:100681771:100681863:1006819900.29301.9937e-025.2307e-080.4266imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_GLYCOLYSIS
ENSG00000137413.14,TAF8
TGCTEAGIRENSG00000146830.9chr7100679506:100681771:100681863:1006819900.27103.8821e-021.9186e-070.4098imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_GLYCOLYSIS
chr6:42077758-42082418:+
TGCTEERA5ENSG00000170222.11chr1710706437:10706550:10704909:10705527:10704909:107056150.26974.1578e-021.2366e-070.4221imageNADAR;DGCR8;HNRNPA1;IGF2BP2;NOP58;TAF15;TARDBP;U2AF2NAB_cells_naiveGSVA_HALLMARK_MTORC1_SIGNALING
chr6:42077758-42082418:+
TGCTEERMEXENSG00000104529.13chr8143586753:143586852:143588990:143590738:143596878:143597074:143597347:143597415-0.28622.8577e-022.8685e-07-0.4019imageNADAR;DGCR8;DHX9;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
chr6:42077758-42082418:+
TGCTEERA5ENSG00000185917.9chr2136058815:36058924:36060346:36060363:36060281:36060363-0.25292.4601e-024.4261e-06-0.4133imageNADAR;DGCR8;HNRNPA1;IGF2BP2;NOP58;SF3B4;TAF15;TARDBP;U2AF2NAGSVA_HALLMARK_MTORC1_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for TAF8


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr6:42077758-42082418:+ACCEEREosinophils2.4623e-020.2704image
ENSG00000137413.14,TAF8ACCEAGEosinophils2.4771e-020.2702image
chr6:42077758-42082418:+BLCAEERMonocytes1.2463e-02-0.1250image
ENSG00000137413.14,TAF8BLCAEAGMonocytes1.0271e-02-0.1282image
chr6:42077758-42082418:+BRCAEERB_cells_naive3.6466e-02-0.0639image
chr6:42077758-42082418:+CHOLEERMacrophages_M11.5589e-020.4058image
ENSG00000137413.14,TAF8CHOLEAGMacrophages_M11.4534e-020.4096image
chr6:42077758-42082418:+COADEEREosinophils2.2847e-050.2556image
ENSG00000137413.14,TAF8COADEAGEosinophils2.1736e-050.2562image
chr6:42077758-42082418:+DLBCEERMacrophages_M21.8127e-020.3398image
ENSG00000137413.14,TAF8DLBCEAGMonocytes8.6059e-030.3752image
chr6:42077758-42082418:+ESCAEERT_cells_CD4_memory_activated1.7281e-030.2451image
ENSG00000137413.14,TAF8ESCAEAGT_cells_CD4_memory_activated1.6866e-030.2456image
chr6:42077758-42082418:+GBMEERPlasma_cells2.3178e-030.2437image
ENSG00000137413.14,TAF8GBMEAGPlasma_cells6.9490e-030.2153image
chr6:42077758-42082418:+KICHEERDendritic_cells_activated6.9884e-03-0.3340image
ENSG00000137413.14,TAF8KICHEAGT_cells_CD82.5751e-020.2787image
chr6:42077758-42082418:+KIRCEERB_cells_memory5.2072e-060.2347image
ENSG00000137413.14,TAF8KIRCEAGB_cells_memory1.1925e-060.2484image
chr6:42077758-42082418:+KIRPEERT_cells_CD4_memory_activated4.0882e-030.1733image
ENSG00000137413.14,TAF8KIRPEAGT_cells_CD4_memory_activated3.9466e-030.1739image
ENSG00000137413.14,TAF8LAMLEAGB_cells_memory2.6662e-02-0.1937image
chr6:42077758-42082418:+LGGEERNeutrophils4.7241e-020.0873image
ENSG00000137413.14,TAF8LGGEAGB_cells_memory2.0746e-020.1016image
chr6:42077758-42082418:+LIHCEERT_cells_gamma_delta4.8085e-03-0.1493image
ENSG00000137413.14,TAF8LIHCEAGT_cells_gamma_delta7.5780e-03-0.1413image
chr6:42077758-42082418:+LUADEERT_cells_gamma_delta3.8216e-040.1581image
ENSG00000137413.14,TAF8LUADEAGT_cells_gamma_delta2.8038e-040.1615image
chr6:42077758-42082418:+LUSCEERMonocytes3.5231e-02-0.0951image
ENSG00000137413.14,TAF8LUSCEAGMonocytes2.7888e-02-0.0992image
chr6:42077758-42082418:+MESOEERT_cells_follicular_helper1.4959e-020.2679image
ENSG00000137413.14,TAF8MESOEAGT_cells_follicular_helper1.2985e-020.2733image
chr6:42077758-42082418:+OVEERT_cells_gamma_delta3.9962e-030.1697image
ENSG00000137413.14,TAF8OVEAGT_cells_gamma_delta5.9589e-030.1622image
chr6:42077758-42082418:+PAADEERT_cells_CD4_memory_activated1.3678e-02-0.1877image
ENSG00000137413.14,TAF8PAADEAGT_cells_CD4_memory_activated7.6333e-03-0.2028image
chr6:42077758-42082418:+PCPGEERNK_cells_activated1.6577e-02-0.1846image
ENSG00000137413.14,TAF8PCPGEAGNK_cells_activated8.8006e-03-0.2009image
ENSG00000137413.14,TAF8READEAGNK_cells_activated4.2002e-02-0.2113image
chr6:42077758-42082418:+SARCEERT_cells_CD82.0787e-02-0.1459image
ENSG00000137413.14,TAF8SARCEAGT_cells_CD81.8867e-02-0.1481image
chr6:42077758-42082418:+SKCMEERDendritic_cells_activated5.0987e-040.1616image
ENSG00000137413.14,TAF8SKCMEAGDendritic_cells_activated4.9551e-040.1616image
chr6:42077758-42082418:+STADEERT_cells_CD4_memory_activated8.2594e-050.2043image
ENSG00000137413.14,TAF8STADEAGT_cells_CD4_memory_activated2.2594e-040.1916image
chr6:42077758-42082418:+TGCTEERMacrophages_M15.2198e-030.2255image
ENSG00000137413.14,TAF8TGCTEAGMacrophages_M15.4045e-030.2246image
chr6:42077758-42082418:+THCAEERT_cells_CD4_naive1.3640e-02-0.1100image
ENSG00000137413.14,TAF8THCAEAGT_cells_CD4_naive3.7316e-03-0.1291image
chr6:42077758-42082418:+UCECEERT_cells_regulatory_(Tregs)2.1294e-02-0.1771image


Top

6. Enriched editing regions and immune gene sets for TAF8


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr6:42077758-42082418:+BLCAEER1.0515e-02image1.6136e-030.1574image
ENSG00000137413.14,TAF8BLCAEAG1.7398e-02image6.1737e-040.1705image
chr6:42077758-42082418:+LUSCEER6.1900e-03image4.7214e-020.0897image
ENSG00000137413.14,TAF8LUSCEAG8.7649e-03image3.1984e-020.0968image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr6:42077758-42082418:+BLCAGSVA_HALLMARK_ANGIOGENESISEER8.9463e-040.1657image
ENSG00000137413.14,TAF8BLCAGSVA_HALLMARK_ANGIOGENESISEAG3.3124e-040.1786image
ENSG00000137413.14,TAF8BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.3752e-060.1468image
chr6:42077758-42082418:+BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.7232e-060.1428image
chr6:42077758-42082418:+CESCGSVA_HALLMARK_ADIPOGENESISEER4.3778e-020.1163image
ENSG00000137413.14,TAF8CESCGSVA_HALLMARK_ADIPOGENESISEAG4.6712e-020.1147image
chr6:42077758-42082418:+CHOLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.5442e-02-0.3567image
ENSG00000137413.14,TAF8CHOLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.8038e-02-0.3521image
ENSG00000137413.14,TAF8COADGSVA_HALLMARK_MYOGENESISEAG6.0246e-03-0.1674image
chr6:42077758-42082418:+COADGSVA_HALLMARK_MYOGENESISEER6.6784e-03-0.1653image
ENSG00000137413.14,TAF8ESCAGSVA_HALLMARK_MYC_TARGETS_V1EAG2.1590e-040.2876image
chr6:42077758-42082418:+ESCAGSVA_HALLMARK_MYC_TARGETS_V1EER1.4083e-040.2956image
ENSG00000137413.14,TAF8GBMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG3.0723e-02-0.1731image
ENSG00000137413.14,TAF8HNSCGSVA_HALLMARK_SPERMATOGENESISEAG1.6334e-04-0.1690image
chr6:42077758-42082418:+HNSCGSVA_HALLMARK_SPERMATOGENESISEER2.0211e-04-0.1668image
ENSG00000137413.14,TAF8KIRCGSVA_HALLMARK_GLYCOLYSISEAG8.4163e-040.1722image
chr6:42077758-42082418:+KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER4.2344e-04-0.1826image
ENSG00000137413.14,TAF8LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.7263e-02-0.1929image
chr6:42077758-42082418:+LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER6.6049e-04-0.1493image
ENSG00000137413.14,TAF8LGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG7.8667e-05-0.1726image
chr6:42077758-42082418:+LIHCGSVA_HALLMARK_MYC_TARGETS_V2EER1.8067e-05-0.2254image
ENSG00000137413.14,TAF8LIHCGSVA_HALLMARK_MYC_TARGETS_V2EAG5.5486e-06-0.2381image
chr6:42077758-42082418:+LUADGSVA_HALLMARK_HYPOXIAEER1.7887e-050.1904image
ENSG00000137413.14,TAF8LUADGSVA_HALLMARK_HYPOXIAEAG1.7720e-050.1903image
chr6:42077758-42082418:+LUSCGSVA_HALLMARK_HYPOXIAEER4.4290e-040.1581image
ENSG00000137413.14,TAF8LUSCGSVA_HALLMARK_HYPOXIAEAG2.4209e-040.1649image
ENSG00000137413.14,TAF8MESOGSVA_HALLMARK_DNA_REPAIREAG1.5273e-02-0.2671image
chr6:42077758-42082418:+MESOGSVA_HALLMARK_DNA_REPAIREER1.7477e-02-0.2619image
chr6:42077758-42082418:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.6702e-040.2208image
ENSG00000137413.14,TAF8OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.0562e-050.2572image
ENSG00000137413.14,TAF8PAADGSVA_HALLMARK_HEME_METABOLISMEAG6.5735e-03-0.2065image
chr6:42077758-42082418:+PAADGSVA_HALLMARK_HEME_METABOLISMEER8.9471e-03-0.1988image
chr6:42077758-42082418:+PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER5.6203e-040.2634image
ENSG00000137413.14,TAF8PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.4506e-030.2431image
ENSG00000137413.14,TAF8PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.0446e-02-0.1150image
chr6:42077758-42082418:+PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.6415e-02-0.1079image
ENSG00000137413.14,TAF8READGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.3903e-040.3722image
chr6:42077758-42082418:+READGSVA_HALLMARK_ANDROGEN_RESPONSEEER5.3327e-040.3523image
ENSG00000137413.14,TAF8SARCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.5418e-030.1834image
chr6:42077758-42082418:+SARCGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.1323e-030.1930image
ENSG00000137413.14,TAF8SKCMGSVA_HALLMARK_GLYCOLYSISEAG1.1786e-030.1506image
chr6:42077758-42082418:+SKCMGSVA_HALLMARK_GLYCOLYSISEER5.6061e-040.1604image
chr6:42077758-42082418:+STADGSVA_HALLMARK_MITOTIC_SPINDLEEER2.6444e-06-0.2427image
ENSG00000137413.14,TAF8STADGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.4133e-08-0.2835image
ENSG00000137413.14,TAF8TGCTGSVA_HALLMARK_MTORC1_SIGNALINGEAG3.1279e-080.4304image
chr6:42077758-42082418:+TGCTGSVA_HALLMARK_MTORC1_SIGNALINGEER2.9501e-080.4311image
chr6:42077758-42082418:+THCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.6309e-020.0935image
ENSG00000137413.14,TAF8THCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.2924e-020.0903image
chr6:42077758-42082418:+THYMGSVA_HALLMARK_BILE_ACID_METABOLISMEER4.1612e-02-0.1895image
ENSG00000137413.14,TAF8UCECGSVA_HALLMARK_HYPOXIAEAG3.9129e-020.1579image
chr6:42077758-42082418:+UCECGSVA_HALLMARK_HYPOXIAEER2.1311e-020.1770image
ENSG00000137413.14,TAF8UVMGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.0949e-03-0.3748image
chr6:42077758-42082418:+UVMGSVA_HALLMARK_UV_RESPONSE_DNEER3.7535e-03-0.3573image


Top

7. Enriched editing regions and drugs for TAF8


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr6:42077758-42082418:+ACCBicalutamideEER2.1506e-02-0.2764image
ENSG00000137413.14,TAF8ACCBicalutamideEAG1.5714e-02-0.2898image
chr6:42077758-42082418:+BLCAIPA.3EER4.3965e-030.1423image
ENSG00000137413.14,TAF8BLCAIPA.3EAG1.7998e-030.1556image
ENSG00000137413.14,TAF8BRCAA.770041EAG2.1925e-03-0.0935image
chr6:42077758-42082418:+BRCAA.770041EER2.0778e-03-0.0941image
ENSG00000137413.14,TAF8CESCBMS.536924EAG4.8401e-02-0.1142image
chr6:42077758-42082418:+CESCBMS.536924EER4.3943e-02-0.1166image
chr6:42077758-42082418:+CHOLGSK.650394EER1.7602e-030.5098image
ENSG00000137413.14,TAF8CHOLGSK.650394EAG1.7955e-030.5089image
ENSG00000137413.14,TAF8COADBexaroteneEAG3.2949e-030.1789image
chr6:42077758-42082418:+COADBexaroteneEER3.7326e-030.1766image
chr6:42077758-42082418:+ESCADocetaxelEER1.1939e-03-0.2532image
ENSG00000137413.14,TAF8ESCABI.D1870EAG1.9060e-03-0.2429image
chr6:42077758-42082418:+GBMGW843682XEER1.0881e-020.2047image
ENSG00000137413.14,TAF8GBMBosutinibEAG4.0797e-040.2796image
ENSG00000137413.14,TAF8HNSCBMS.708163EAG3.5082e-08-0.2452image
chr6:42077758-42082418:+HNSCBMS.708163EER8.3456e-08-0.2387image
ENSG00000137413.14,TAF8KIRCATRAEAG3.7738e-040.1832image
chr6:42077758-42082418:+KIRCATRAEER1.0555e-040.2005image
ENSG00000137413.14,TAF8KIRPIPA.3EAG3.3130e-040.2157image
chr6:42077758-42082418:+KIRPGSK.650394EER3.3820e-040.2154image
ENSG00000137413.14,TAF8LAMLMethotrexateEAG4.4682e-030.2469image
chr6:42077758-42082418:+LGGBMS.708163EER2.1159e-04-0.1622image
ENSG00000137413.14,TAF8LGGEmbelinEAG1.8277e-030.1366image
chr6:42077758-42082418:+LIHCIPA.3EER1.6652e-040.1988image
ENSG00000137413.14,TAF8LIHCAZD.2281EAG1.0650e-040.2062image
chr6:42077758-42082418:+LUADGemcitabineEER2.0175e-03-0.1376image
ENSG00000137413.14,TAF8LUADGemcitabineEAG6.9086e-04-0.1510image
ENSG00000137413.14,TAF8LUSCIPA.3EAG2.9811e-050.1872image
chr6:42077758-42082418:+LUSCIPA.3EER2.3253e-050.1899image
chr6:42077758-42082418:+MESOCHIR.99021EER3.6950e-03-0.3171image
ENSG00000137413.14,TAF8MESOCHIR.99021EAG3.9525e-03-0.3149image
chr6:42077758-42082418:+OVBMS.509744EER4.0968e-05-0.2400image
ENSG00000137413.14,TAF8OVBMS.509744EAG2.8744e-06-0.2726image
ENSG00000137413.14,TAF8PAADBMS.708163EAG3.0940e-040.2718image
chr6:42077758-42082418:+PAADBMS.708163EER3.4211e-040.2699image
ENSG00000137413.14,TAF8PCPGDMOGEAG8.5384e-04-0.2542image
chr6:42077758-42082418:+PCPGDMOGEER9.4980e-04-0.2527image
ENSG00000137413.14,TAF8PRADJNJ.26854165EAG5.9910e-040.1537image
chr6:42077758-42082418:+PRADJNJ.26854165EER2.0119e-040.1665image
chr6:42077758-42082418:+READBMS.708163EER6.8640e-03-0.2785image
ENSG00000137413.14,TAF8READBMS.708163EAG5.4886e-03-0.2858image
ENSG00000137413.14,TAF8SARCBIRB.0796EAG2.2363e-040.2310image
chr6:42077758-42082418:+SARCBIRB.0796EER3.0244e-040.2262image
ENSG00000137413.14,TAF8SKCMAP.24534EAG3.0744e-030.1376image
chr6:42077758-42082418:+SKCMAP.24534EER9.3585e-040.1540image
chr6:42077758-42082418:+STADCisplatinEER5.2262e-06-0.2356image
chr6:42084688-42085983:+STADAZD6244EER7.4549e-030.4946image
ENSG00000137413.14,TAF8STADCisplatinEAG4.4438e-06-0.2373image
ENSG00000137413.14,TAF8TGCTDocetaxelEAG3.3054e-04-0.2874image
chr6:42077758-42082418:+TGCTDocetaxelEER1.5544e-04-0.3021image
chr6:42077758-42082418:+THCABexaroteneEER9.5748e-060.1961image
ENSG00000137413.14,TAF8THCABexaroteneEAG2.4060e-050.1871image
chr6:42077758-42082418:+THYMDocetaxelEER3.9012e-02-0.1919image
ENSG00000137413.14,TAF8UCECDMOGEAG7.8366e-05-0.2973image
chr6:42077758-42082418:+UCECDMOGEER1.4747e-04-0.2879image
chr6:42077758-42082418:+UCSIPA.3EER2.7999e-020.2937image
ENSG00000137413.14,TAF8UCSIPA.3EAG2.6933e-020.2957image
chr6:42077758-42082418:+UVMDasatinibEER2.0791e-05-0.5051image
ENSG00000137413.14,TAF8UVMDasatinibEAG8.1242e-06-0.5222image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType